Front. Med.Frontiers in MedicineFront. Med.2296-858XFrontiers Media S.A.10.3389/fmed.2025.1620932MedicineCorrectionCorrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edemaZhaiGaixiaSunChaoZhangXiaSuYuanzhen*Zibo Central Hospital, Zibo, China
Edited and reviewed by: Yi Du, The First Affiliated Hospital of Guangxi Medical University, China
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema by Zhai, G., Sun, C., Zhang, X., and Su, Y. (2025). Front. Med. 12:1528104. doi: 10.3389/fmed.2025.1528104aflibercept biosimilardiabetic macular edemafoveal avascular zonevascular densitymultifocal electroretinographysection-at-acceptanceOphthalmology
In the published article, the reference for (5) was incorrectly written as “Georgalas, L, Tservakis, I, Kiskira, EE, Petrou, P, Papaconstantinou, D, and Kanakis, M. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:330–7. doi: 10.31348/2025/4.” It should be “Berhuni M, Yılmaz İE, Gizem GS, Özcan ZÖ, Doğan L. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:1–6. doi: 10.31348/2025/4.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesBerhuniMYılmazİEGizemGSÖzcanZÖDoğanL. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:1–6. 10.31348/2025/439891556